Seeking Alpha

Seeking Alpha Portfolio App for iPad

22,685 people get PFE articles and Market Currents by email alert.

Get email alerts on PFE »

PFE

Pfizer Inc.

5/19/2013, 4:20 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 8:12 AM Pain Therapeutics (PTIE) craters 45.5% in premarket trading after Pfizer (PFE) says it is "considering its options" on Remoxy and may not respond to the FDA's complete response letter anytime in the next two years. PTIE sub-licensed Remoxy's commercialization rights to PFE subsidiary King Pharma (I, II). Comment! [Healthcare, On the Move]
Friday, May 10, 7:46 AM Pfizer (PFE) updates Durect (DRRX) on Remoxy, saying that it's "considering its options", and that if it elects to continue development of Remoxy, "we would not expect to submit a response to the "complete response" letter before mid-2015." (PR) This is less positive than expected by SA author Jason Napodano; shares are -12.6% premarket. 1 Comment [Healthcare, On the Move, Breaking News]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, May 6, 9:38 AM More on Pfizer (PFE -0.5%): A plan by the company to sell Viagra online is motivated by the estimated hundreds of millions of dollars it loses to counterfeit versions of the drug found online. A ticking clock for patent expiration (2020) in the U.S. could also be a factor. To attract new customers, Pfizer will reportedly become more promotional with Viagra by offering three free pills with the first order and then 30% off order number two. 3 Comments [Healthcare]
Monday, May 6, 9:23 AM Pfizer (PFE) plans to start selling Viagra online, according to an AP report. The initiative could serve as a test run by Big Pharma over disrupting its current model to look at online distribution for treatments viewed as more embarrassing to buy in person. Drugstore operators (CVS, WAG, RAD) will be watching the development very carefully. PFE -0.1% premarket. 2 Comments [Healthcare, Consumer]
Tuesday, April 30, 11:41 AM Pain Therapeutics (PTIE +19%) and Durect (DRRX +25.5%) both soar on the back of positive comments out of Pfizer's (PFE) conference call about Remoxy, an oxycodone capsule the pair have been developing. PTIE sub-licensed Remoxy's commercialization rights to King Pharmaceuticals, which is a subsidiary of PFE, and the pharma-giant noted in its call that it's had a productive meeting with the FDA last month regarding the drug. (PFE Conference Call Webcast) 1 Comment [Healthcare, On the Move]
Tuesday, April 30, 7:21 AM More on Pfizer (PFE) Q1 earnings: Sales fell 9% Y/Y - 8% operational, 1% unfavorable fx adjustment. Much of the operational decrease due to loss of exclusivity of Lipitor. Emerging markets revenue +6%. Adjusted cost of sales fell 7%. FY2013 revenue guidance reduced to $55.3B-$57.3B from $56.2B-$58.2B. Adjusted EPS of $2.14-$2.24 from $2.20-$2.30. About $8B in share repurchases YTD, "with significant additional capital expected to be allocated ... for the remainder of the year." Shares -2.2% premarket. Conference call at 10 ET. (PR) 4 Comments [Healthcare, Earnings, On the Move]
Tuesday, April 30, 7:01 AM Pfizer (PFE): Q1 EPS of $0.54 misses by $0.01. Revenue of $13.5B misses by $0.6B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 30, 12:05 AM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS Comment! [Earnings]
Monday, April 29, 5:30 PM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS 1 Comment [Earnings]
Monday, April 29, 8:18 AM Protalix BioTherapeutics (PLX) rises 6% premarket as its Type I Gaucher disease treatment UPLYSO ("ELELYSO" outside of Latin America) gains approval in Mexico and Chile — it is already approved in the U.S., Israel, and Brazil. The company develops and commercializes the drug with Pfizer (PFE). (PR) Comment! [Healthcare, On the Move]
Monday, April 29, 7:55 AM Merck (MRK) and Pfizer (PFE) enter into a 60/40 worldwide agreement to jointly develop and commercialize PFE's type 2 diabetes treatment ertugliflozin which should enter Phase III trials later this year. As part of the deal, PFE received $60M upfront and may receive additional payments in the future. (PR) 3 Comments [Healthcare]
Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]
Thursday, April 25, 7:20 PM The European Medicines Agency has recommended against approval of Pfizer's (PFE) new arthritis drug Xeljanz, which was approved by US FDA last year. Committee cites concerns about drug's efficacy and safety. ISI Group says the European component of Xeljanz represents 25% of sales, and failure to launch there would trim its EPS by up to 3% by 2017. Shares -2.5% AH. Comment! [Healthcare, Global & FX, On the Move]
Thursday, April 25, 2:12 PM Pfizer Inc. (PFE) declares $0.24/share quarterly dividend, in line with previous. Forward yield 3.15%. For shareholders of record May 10. Payable June 04. Ex-div date May 08. (PR) 1 Comment [Dividends]
Wednesday, April 17, 10:56 AM Shares of Pain Therapeutics (PTIE +1.4%) benefit from the FDA's "public health priority" call on abuse-deterrent opioid analgesics. PTIE is developing Remoxy, an abuse-resistant form of oxycodone in conjunction with Pfizer (PFE). Other names moving on the news: ACUR +70% and ENDP +3.2%. Comment! [Healthcare, On the Move]

1
2
3
4
5
6
...
41
Next Page